

(Correction) Partial corrections of “Notice Regarding Determination of Payment Amount and Other Matters of Issuance of New Shares Under Restricted Stock Unit (RSU) Plan”

Tokyo, Japan and Cambridge, UK, 20 April 2022 – Sosei Group Corporation (“the Company”; TSE: 4565) announces it has made partial corrections of “Notice Regarding Determination of Payment Amount and Other Matters of Issuance of New Shares Under Restricted Stock Unit (RSU) Plan” announced on April 8, 2022, as per below. The corrected parts are shown with underlines.

[Before the correction]

(1) Payment date	19 May 2022
(2) Type and number of shares to be issued	<u>207,030</u> shares of the Company’s common stock
(3) Payment amount	1,427 Yen per share
(4) Total amount of payment	<u>295,431,810</u> Yen
(5) Allottees	7 Directors and Executive Officers of the Company <u>52</u> Directors of subsidiaries of the Company and employees of the Company and its subsidiaries
(6) Other details	The Securities Registration Statement relating to the Share Issuance has been filed in accordance with the Financial Instruments and Exchange Act.

[After the correction]

(1) Payment date	19 May 2022
(2) Type and number of shares to be issued	<u>208,392</u> shares of the Company’s common stock
(3) Payment amount	1,427 Yen per share
(4) Total amount of payment	<u>297,375,384</u> Yen
(5) Allottees	7 Directors and Executive Officers of the Company <u>53</u> Directors of subsidiaries of the Company and employees of the Company and its subsidiaries
(6) Other details	The Securities Registration Statement relating to the Share Issuance has been filed in accordance with the Financial Instruments and Exchange Act.

-ENDS-

A solid orange circle is positioned to the left of the blue bar.

PRESS RELEASE

About Sosei Heptares

We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR[®] technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology, and inflammatory diseases.

We have established partnerships with some of the world's leading pharmaceutical companies and multiple emerging biotechnology companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Neurocrine Biosciences, Novartis, Pfizer, Takeda and Verily. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.

“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR[®] are trademarks of Sosei Group companies.

For more information, please visit <https://soseiheptares.com/>
LinkedIn: [@soseiheptaresco](#) | Twitter: [@soseiheptaresco](#) | YouTube: [@soseiheptaresco](#)

Enquiries:

Sosei Heptares – Media and Investor Relations

Hironoshin Nomura, CFO
+81 (0)3 6679 2178 | Hironoshin.Nomura@SoseiHeptares.com

Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures
+81 (0)3 5210 3399 | IR@SoseiHeptares.com

MEDiSTRAVA Consulting (for International Media)

Mark Swallow, David Dible, Eleanor Perkin
+44 (0)203 928 6900 | SoseiHeptares@medistrava.com

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Sosei Group Corporation's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.